Technique kills cancerous cells, leaves healthy cells intact

December 01, 2003

CHAMPAIGN, Ill. -- Chemists at the University of Illinois at Urbana-Champaign have produced a molecule that selectively kills cancerous cells in a desired way and leaves healthy cells virtually untouched.

While encouraging, the findings don't mean a new treatment is imminent. The basic laboratory experiments were done in microtiter dishes, where the compound was simply exposed to leukemia and lymphoma cells and healthy white blood cells from mice.

"It's hard to say where this discovery may fit into the big picture, but the pathway we've found is real; it is very provocative," said Paul J. Hergenrother, a professor of chemistry, who directed the study funded by the National Science Foundation.

The study appears in the Dec. 3 issue of the Journal of the American Chemical Society. The compound, which is referred to as 13-D in the study, already is being tested by the National Cancer Institute. The University of Illinois has applied for a patent on it.

"The next big step would be to show that this compound works in an animal model," Hergenrother said. "We are very interested in the selectivity of this compound. We now are trying to track down exactly what protein target this compound is binding to in the cancer cells. If we can isolate the protein receptor, we may find a totally new anti-cancer target."

Hergenrother and his doctoral students Vitaliy Nesterenko and Karson S. Putt manufactured a library of 88 artificial compounds based on the structures of certain natural products. Three of the compounds showed a significant ability to kill cancer cells. Those three were further screened to determine if they were killing the cancer cells through apoptosis or necrosis.

Apoptosis is desired because cells die in a programmed fashion and are simply engulfed by other cells. Necrosis is essentially an accidental breakdown that results in the spilling of cellular material that triggers an undesirable anti-inflammatory response.

Compound 13-D was found to have the strongest cancer-killing effect and the only one to induce a cysteine protease known as caspase-3 as well as blebbing (a pinching off of the cellular membrane) and cell shrinkage, all of which are hallmarks of apoptosis.

"Once we had a compound that killed by apoptosis, we did the key experiment to see if the compound induced cell death selectively, choosing cancerous cells over non-cancerous white blood cells," Hergenrother said. "Compound 13-D showed virtually no toxicity toward the actively dividing T-cells while almost completely killing the lymphoma and leukemia cells."

Such results are desirable, because many current human therapeutic approaches result in undesired side effects such as anemia and major gastrointestinal problems.

Additionally, Hergenrother said, if the biological pathways can be isolated it may be possible to manufacture compounds that not only encourage apoptosis in cancer cells but also inhibit it in healthy cells, a potential benefit to sufferers of Alzheimer's and Parkinson's diseases in which many cells die off unnecessarily.
-end-


University of Illinois at Urbana-Champaign

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.